Richard J. Rodgers's Insider Trades & SAST Disclosures
Richard J. Rodgers's most recent trade in Opus Genetics Inc. was a trade of 79,592 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on April 30, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Richard J. Rodgers.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Opus Genetics Inc. | Rodgers J. Richard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2025 | 79,592 | 79,592 | - | - | Stock Option (Right to Buy) | |
| Opus Genetics Inc. | Rodgers J. Richard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2025 | 79,504 | 318,655 | - | 0 | Common Stock | |
| Ardelyx Inc | Richard J. Rodgers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.55 per share. | 16 Jan 2025 | 100,000 | 350,524 (0%) | 0% | 0.6 | 55,000 | Common Stock |
| Ardelyx Inc | Richard J. Rodgers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2025 | 100,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Rodgers Richard J. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Oct 2024 | 3,800 | 14,270 (0%) | 0% | 0 | Common Stock | |
| Novavax, Inc. | Richard J. Rodgers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Oct 2024 | 3,800 | 3,800 | - | - | Restricted Stock Units | |
| Ardelyx Inc | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 40,243 | 40,243 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 12,204 | 250,524 (0%) | 0% | 0 | Common Stock | |
| Novavax, Inc. | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 15,630 | 15,630 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 10,420 | 10,420 | - | - | Restricted Stock Units | |
| Novavax, Inc. | Richard J. Rodgers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2024 | 6,670 | 0 | - | - | Restricted Stock Units | |
| Novavax, Inc. | Richard J. Rodgers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2024 | 6,670 | 10,470 (0%) | 0% | 0 | Common Stock | |
| Opus Genetics Inc. | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 41,143 | 239,151 | - | 0 | Common Stock | |
| Opus Genetics Inc. | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 35,181 | 35,181 | - | - | Stock Option (Right to Buy) | |
| Opus Genetics Inc. | J. Richard Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 24,762 | 198,008 | - | - | Common Stock | |
| Novavax, Inc. | Richard J. Rodgers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Oct 2023 | 3,800 | 7,600 | - | - | Restricted Stock Units | |
| Novavax, Inc. | Richard J. Rodgers | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Oct 2023 | 3,800 | 3,800 (0%) | 0% | - | Common Stock | |
| Sagimet Biosciences Inc - ... | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 23,839 | 23,839 | - | - | Stock Option (Right to Buy) | |
| Sagimet Biosciences Inc - ... | Richard J. Rodgers | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 23,839 | 0 | - | - | Stock Option (Right to Buy) | |
| Sagimet Biosciences Inc - ... | Richard J. Rodgers | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 23,216 | 0 | - | - | Stock Option (Right to Buy) | |
| Sagimet Biosciences Inc - ... | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 23,216 | 23,216 | - | - | Stock Option (Right to Buy) | |
| Sagimet Biosciences Inc - ... | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 1,976 | 1,976 | - | - | Stock Option (Right to Buy) | |
| Sagimet Biosciences Inc - ... | Richard J. Rodgers | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 1,976 | 0 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 49,237 | 49,237 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 18,494 | 238,320 (0%) | 0% | 0 | Common Stock | |
| Novavax, Inc. | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2023 | 7,710 | 7,710 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2023 | 6,670 | 6,670 | - | - | Restricted Stock Units | |
| Opus Genetics Inc. | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2023 | 20,822 | 88,246 | - | - | Common Stock | |
| Novavax, Inc. | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2022 | 17,095 | 17,095 | - | - | Stock Option (Right to buy) | |
| Novavax, Inc. | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2022 | 11,400 | 11,400 | - | - | Restricted Stock Units | |
| Opus Genetics Inc. | Richard J. Rodgers | Director | 03 Oct 2022 | 3,148 | 0 | - | - | Series B Warrant (right to buy) | ||
| Opus Genetics Inc. | Richard J. Rodgers | Director | 03 Oct 2022 | 3,148 | 67,424 | - | 0 | Common Stock | ||
| Opus Genetics Inc. | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 15,841 | 64,276 | - | - | Common Stock | |
| Opus Genetics Inc. | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 7,812 | 48,435 | - | - | Common Stock | |
| Ardelyx Inc | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 132,299 | 219,826 (0%) | 0% | 0 | Common Stock | |
| Ardelyx Inc | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Opus Genetics Inc. | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Opus Genetics Inc. | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 4,629 | 40,623 | - | - | Common Stock | |
| Opus Genetics Inc. | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 4,021 | 35,994 | - | - | Common Stock | |
| Opus Genetics Inc. | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 2,912 | 31,973 | - | - | Common Stock | |
| Opus Genetics Inc. | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 2,840 | 29,061 | - | - | Common Stock | |
| Ardelyx Inc | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 32,765 | 32,765 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 9,917 | 87,527 (0%) | 0% | 0 | Common Stock | |
| Opus Genetics Inc. | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Opus Genetics Inc. | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 2,581 | 26,221 | - | - | Common Stock | |
| Opus Genetics Inc. | Richard J. Rodgers | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 19 Nov 2020 | 26,789 | 26,789 | - | - | Series A Warrant (right to buy) | |
| Opus Genetics Inc. | Richard J. Rodgers | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 19 Nov 2020 | 17,730 | 23,640 | - | - | Common Stock | |
| Opus Genetics Inc. | Richard J. Rodgers | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 19 Nov 2020 | 3,148 | 3,148 | - | - | Series B Warrant (right to buy) | |
| Opus Genetics Inc. | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Nov 2020 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Ardelyx Inc | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2020 | 23,500 | 23,500 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2020 | 9,233 | 77,610 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges